Compare IDYA & IMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDYA | IMAX |
|---|---|---|
| Founded | 2015 | 1967 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2019 | 1997 |
| Metric | IDYA | IMAX |
|---|---|---|
| Price | $34.91 | $44.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 10 |
| Target Price | ★ $52.86 | $44.50 |
| AVG Volume (30 Days) | ★ 1.2M | 882.9K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | 31.25 |
| EPS | N/A | ★ 0.07 |
| Revenue | $218,710,000.00 | ★ $410,212,000.00 |
| Revenue This Year | N/A | $9.79 |
| Revenue Next Year | $201.05 | $7.51 |
| P/E Ratio | ★ N/A | $628.57 |
| Revenue Growth | ★ 3024.43 | 16.47 |
| 52 Week Low | $20.50 | $24.20 |
| 52 Week High | $39.28 | $45.16 |
| Indicator | IDYA | IMAX |
|---|---|---|
| Relative Strength Index (RSI) | 69.60 | 73.76 |
| Support Level | $32.85 | $33.57 |
| Resistance Level | $36.01 | N/A |
| Average True Range (ATR) | 1.80 | 1.44 |
| MACD | 0.67 | 0.35 |
| Stochastic Oscillator | 92.17 | 95.97 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.